SIRT2 mediated downregulation of FOXM1 in response to TGFβ through the RAF-MEK-ERK signaling pathway in colon cancer

Authors

DOI:

https://doi.org/10.2298/ABS210227020O

Keywords:

deacetylation, colon cancer, FOXM1, SIRT2, posttranslational

Abstract

Paper description:

  • The Forkhead Box M1 (FOXM1) oncogenic transcription factor is upregulated in many malignancies, including colorectal cancer.
  • Removal or silencing of Sirtuin 2 (SIRT2) upregulates FOXM1 through the transforming growth factor-beta (TGFβ mitogen-activated protein kinase (RAF-MEK-ERK) signaling pathway in both SIRT2 knockout mouse embryonic fibroblasts and SIRT2 knocked-down HCT116 colon cancer cells.
  • SIRT2 overexpression in HCT116 cells decreased the number of colony formations and lengthened the doubling time.
  • The intracellular distribution of FOXM1 was independent of SIRT2 overexpression in HCT116 cells.

Abstract: The transcription factor forkhead box M1 (FOXM1) is frequently upregulated in many solid tumors, including those in the colon. As a master regulator, the sirtuin (SIRT) protein family is comprised of seven nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases/adenosine diphosphate (ADP) ribosyl transferases whose activities are associated with aging and cancer. In this study, we determined whether a cytoplasmic member of SIRTs, SIRT2, influences the expression of oncogenic FOXM1 in colon cancer in vitro. The association of SIRT2 and FOXM1 were analyzed using SIRT2 knockout mouse embryonic fibroblasts and SIRT2 knocked-down and overexpressing HCT116 colon cancer cell lines. Cell lines were treated with 10 ng/mL transforming growth factor-beta (TGFb) for 24 h. SIRT2 could downregulate FOXM1 through the TGFb mitogen-activated protein kinase (RAF-MEK-ERK) signaling pathway in genetically altered mouse embryonic fibroblasts and colon cancer cell lines. The indirect association between SIRT2 and FOXM1 through TGFb may be important because activators or inhibitors of SIRT2 could provide a potential approach to downregulate FOXM1 in gastrointestinal cancers.

Downloads

Download data is not yet available.

References

Halasi M, Gartel AL. FOX(M1) news-it is cancer. Mol Cancer Ther 2013;12:245-54. https://doi.org/10.1158/1535-7163.mct-12-0712

Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007;388:1257-74. https://doi.org/10.1515/bc.2007.159

Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochemica. 2012;114:755-62. https://doi.org/10.1016/j.acthis.2012.01.002

Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005;25:10875-94. https://doi.org/10.1128/mcb.25.24.10875-10894.2005

Bektas N, Haaf A, Veeck J, Wild PJ, Luscher-Firzlaff J, Hartmann A, Knuchel R, Dahl E. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer. 2008;8:42. https://doi.org/10.1186/1471-2407-8-42

Ferrer CM, Lu TY, Bacigalupa ZA, Katsetos CD, Sinclair DA, Reginato MJ. O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway. Oncogene. 2017;36:559-69. https://doi.org/10.1038/onc.2016.228

Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 2015;6:2349-65. https://doi.org/10.18632/oncotarget.2957

Zhang J, Zhang J, Cui X, Yang Y, Li M, Qu J, Li J, Wang J. FoxM1: a novel tumor biomarker of lung cancer. Int J Clin Exp Med. 2015;8:3136-40.

Song BN, Chu IS. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma. Exp Mol Med. 2018;50:e418. https://doi.org/10.1038/emm.2017.159

Chong DQ, Shan JL, Yang CS, Wang R, Du ZM. Clinical prognostic value of A FOXM1 related long non-coding RNA expression in gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22:417-21.

Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S, Xie K. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012;72:655-65. https://doi.org/10.1158/0008-5472.can-11-3102

Li D, Wei P, Peng Z, Huang C, Tang H, Jia Z, Cui J, Le X, Huang S, Xie K. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res. 2013;19:62-72. https://doi.org/10.1158/1078-0432.ccr-12-1588

Yang K, Jiang L, Hu Y, Yu J, Chen H, Yao Y, Zhu X. Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation. J Exp Clin Cancer Res. 2015;34:40. https://doi.org/10.1186/s13046-015-0158-1

Nandi D, Cheema PS, Jaiswal N, Nag A. FoxM1: Repurposing an oncogene as a biomarker. Semin Cancer Biol. 2018;52:74-84. https://doi.org/10.1016/j.semcancer.2017.08.009

Xu XS, Miao RC, Wan Y, Zhang LQ, Qu K, Liu C. FoxM1 as a novel therapeutic target for cancer drug therapy. Asian Pac J Cancer Prev. 2015;16:23-9. https://doi.org/10.7314/apjcp.2015.16.1.23

Halasi M, Hitchinson B, Shah BN, Varaljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL. Honokiol is a FOXM1 antagonist. Cell Death Dis. 2018;9:84. https://doi.org/10.1038/s41419-017-0156-7

Yao S, Fan LY, Lam EW. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol. 2018;50:77-89. https://doi.org/10.1016/j.semcancer.2017.11.018

Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, Hu CJ, Bai JY. Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal. 2018;16:57. https://doi.org/10.1186/s12964-018-0266-6

Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 2005;118:795-806. https://doi.org/10.1242/jcs.01657

Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG. Validation of a model of colon cancer progression. J Pathol. 2000;192:446-54. https://doi.org/10.1002/1096-9896(200108)194:4<507::aid-path980>3.0.co;2-4

Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014;106:djt369. https://doi.org/10.1093/jnci/djt369

Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 2015;34:531-6. https://doi.org/10.1038/onc.2013.588

North BJ, Verdin E. Interphase Nucleo-Cytoplasmic Shuttling and Localization of SIRT2 during Mitosis. Plos One. 2007;2(8):e784. https://doi.org/10.1371/journal.pone.0000784

Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20:487-99. https://doi.org/10.1016/j.ccr.2011.09.004

Park SH, Zhu Y, Ozden O, Kim HS, Jiang H, Deng CX, Gius D, Vassilopoulos A. SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl Cancer Res. 2012;1:15-21.

Jing H, Hu J, He B, Negron Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 2016;29:767-8. https://doi.org/10.1016/j.ccell.2016.04.005

Park SH, Ozden O, Liu GX, Song HY, Zhu YM, Yan YF, Zou XH, Kang HJ, Jiang HY, Principe DR, Cha YI, Roh M, Vassilopoulos A, Gius D. SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth. Cancer Res. 2016;76:3802-12. https://doi.org/10.1158/0008-5472.can-15-2498

Ozden O. SIRT2-JAK1 Interaction Decreases IL-6 Induced Inflammatory Response in Cancer Cells. Kafkas Universitesi Veteriner Fakultesi Dergisi. 2015;21:813-7. https://doi.org/10.9775/kvfd.2015.13424

Ozden O, Park SH, Wagner BA, Yong Song H, Zhu Y, Vassilopoulos A, Jung B, Buettner GR, Gius D. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radic Biol Med. 2014;76:163-72. https://doi.org/10.1016/j.freeradbiomed.2014.08.001

Lv CC, Zhao GY, Sun XP, Wang P, Xie N, Luo JY, Tong TJ. Acetylation of FOXM1 is essential for its transactivation and tumor growth stimulation. Oncotarget. 2016;7:60366-82. https://doi.org/10.18632/oncotarget.11332

Park HJ, Wang Z, Costa RH, Tyner A, Lau LF, Raychaudhuri P. An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle. Oncogene. 2008;27:1696-1704. https://doi.org/10.1038/sj.onc.1210814

Alvarez-Fernandez M, Halim VA, Krenning L, Aprelia M, Mohammed S, Heck AJ, Medema RH. Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1. EMBO Rep. 2010;11:452-8. https://doi.org/10.1038/embor.2010.46

Chen YJ, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, Tyner AL, Lau LF, Raychaudhuri P. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem. 2009;284:30695-707. https://doi.org/10.1074/jbc.m109.007997

Pek M, Yatim S, Chen Y, Li J, Gong M, Jiang X, Zhang F, Zheng J, Wu X, Yu Q. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene. 2017;36(35):4975-86. https://doi.org/10.1038/onc.2017.120

Fukuda M, Gotoh I, Adachi M, Gotoh Y, Nishida E. A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J Biol Chem. 1997;272:32642-8. https://doi.org/10.1074/jbc.272.51.32642

Yeung F, Ramsey CS, Popko-Scibor AE, Allison DF, Gray LG, Shin M, Kumar M, Li D, McCubrey JA, Mayo MW. Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases. Oncogene. 2015;34:798-804. https://doi.org/10.1038/onc.2014.39

Watroba M, Szukiewicz D. The role of sirtuins in aging and age-related diseases. Adv Med Sci. 2016;61:52-62. https://doi.org/10.1016/j.advms.2015.09.003

Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H, Oshimura M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2007;26:945-57. https://doi.org/10.1038/sj.onc.1209857

Black JC, Mosley A, Kitada T, Washburn M, Carey M. The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell. 2008;32:449-55. https://doi.org/10.1016/j.molcel.2008.09.018

Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 2007;6:105-14. https://doi.org/10.1016/j.cmet.2007.07.003

Carafa V, Altucci L, Nebbioso A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol. 2019;10:38. https://doi.org/10.3389/fphar.2019.00038

Hagenbuchner J, Ausserlechner MJ. Targeting transcription factors by small compounds--Current strategies and future implications. Biochem Pharmacol. 2016;107:1-13. https://doi.org/10.1016/j.bcp.2015.12.006

Downloads

Published

2021-07-13

How to Cite

1.
Ozden O, Park S-H. SIRT2 mediated downregulation of FOXM1 in response to TGFβ through the RAF-MEK-ERK signaling pathway in colon cancer. Arch Biol Sci [Internet]. 2021Jul.13 [cited 2024Nov.25];73(2):257-64. Available from: https://serbiosoc.org.rs/arch/index.php/abs/article/view/6330

Issue

Vol. 73 No. 2 (2021)

Section

Articles

License

Copyright (c) 2021 Archives of Biological Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.